stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Debt to equity
AstraZeneca PLC's debt to equity at the end of the quarter to 30 September 2026 was 0.6×, up 0.0× from fiscal 2025 (0.6×). Over the past ten years it has ranged from 0.6× (fiscal 2025) to 1.4× (fiscal 2018) — the current reading is the lowest in ten years. That is in line with the Drug Manufacturers General industry median of 0.6× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.6× | (19.09%) |
| FY2024 | 0.7× | 0.53% |
| FY2023 | 0.7× | (8.01%) |
| FY2022 | 0.8× | 0.62% |
| FY2021 | 0.8× | (39.80%) |
| FY2020 | 1.3× | 4.76% |
| FY2019 | 1.2× | (11.64%) |
| FY2018 | 1.4× | 27.19% |
| FY2017 | 1.1× | 6.12% |
| FY2016 | 1.0× | 23.98% |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.6× | 3.55% |
| Jun 2026 | 0.6× | (13.39%) |
| Mar 2026 | 0.7× | 18.39% |
| Dec 2025 | 0.6× | (14.98%) |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ABBV AbbVie Inc. compare | −17.8× |
| AZN AstraZeneca PLC | 0.6× |
| NVO Novo Nordisk A/S compare | 0.6× |
| PFE Pfizer Inc. compare | 0.7× |
| MRK Merck & Co., Inc. compare | 1.2× |
| NVS Novartis AG compare | 1.2× |
| BMY Bristol Myers Squibb Company compare | 1.8× |
| GILD Gilead Sciences, Inc. compare | 2.0× |
| AMGN Amgen Inc. compare | 3.8× |
| Drug Manufacturers General industry median | 0.6× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement